为什么我们还没有找到针对新冠病毒的有效治疗方法？ - Suppr

Suppr

超能文献

Why Haven't We Found an Effective Treatment for COVID-19?

作者信息

Spicer Alexander James, Jalkanen Sirpa

机构信息

MDP Drug Discovery and Development, Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.

MediCity Research Laboratory and Institute of Biomedicine, University of Turku, Turku, Finland.

出版信息

Front Immunol. 2021 Mar 31;12:644850. doi: 10.3389/fimmu.2021.644850. eCollection 2021.

DOI:10.3389/fimmu.2021.644850

PMID:33868280

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8044372/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ed/8044372/68ea46369531/fimmu-12-644850-g001.jpg

相似文献

Why Haven't We Found an Effective Treatment for COVID-19?

Front Immunol. 2021 Mar 31;12:644850. doi: 10.3389/fimmu.2021.644850. eCollection 2021.

Commentary: Why Haven't We Found an Effective Treatment for COVID-19?

Front Immunol. 2021 Jul 5;12:714175. doi: 10.3389/fimmu.2021.714175. eCollection 2021.

The evolution of clinical trials in response to COVID-19.

Med J Aust. 2021 Apr;214(7):332-332.e1. doi: 10.5694/mja2.50991. Epub 2021 Mar 22.

The Biometeorology of COVID-19: A Novel Therapeutic Strategy?

Acta Medica (Hradec Kralove). 2020;63(4):202-204. doi: 10.14712/18059694.2020.65.

Letter from China: Managing the second-wave COVID-19 outbreak in Beijing.

Respirology. 2021 Mar;26(3):275-276. doi: 10.1111/resp.14002. Epub 2021 Jan 5.

Neutrophils in COVID-19.

Front Immunol. 2021 Mar 25;12:652470. doi: 10.3389/fimmu.2021.652470. eCollection 2021.

Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection.

J Biol Chem. 2021 Jan-Jun;296:100135. doi: 10.1074/jbc.REV120.015980. Epub 2020 Dec 6.

Developing Guidelines Before, During, and After the COVID-19 Pandemic.

Ann Intern Med. 2020 Dec 15;173(12):1012-1014. doi: 10.7326/M20-4907. Epub 2020 Sep 15.

COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?

Autoimmun Rev. 2020 Dec;19(12):102683. doi: 10.1016/j.autrev.2020.102683. Epub 2020 Oct 27.

Immunology Lessons from the SARS-CoV-2 Pandemic.

Annu Rev Immunol. 2021 Apr 26;39:v-vii. doi: 10.1146/annurev-iy-39-030121-100001. Epub 2021 May 3.

引用本文的文献

Anti-viral effect of usenamine a using SARS-CoV-2 pseudo-typed viruses.

Heliyon. 2023 Oct 28;9(11):e21742. doi: 10.1016/j.heliyon.2023.e21742. eCollection 2023 Nov.

Treating COVID-19: Targeting the Host Response, Not the Virus.

Life (Basel). 2023 Mar 6;13(3):712. doi: 10.3390/life13030712.

Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19.

Crit Care. 2023 Mar 16;27(1):112. doi: 10.1186/s13054-023-04388-8.

A patchy theoretical model for the transmission dynamics of SARS-Cov-2 with optimal control.

Sci Rep. 2022 Oct 25;12(1):17840. doi: 10.1038/s41598-022-21553-1.

Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease.

Scand J Immunol. 2021 Nov;94(5):e13101. doi: 10.1111/sji.13101. Epub 2021 Sep 16.

Commentary: Why Haven't We Found an Effective Treatment for COVID-19?

Front Immunol. 2021 Jul 5;12:714175. doi: 10.3389/fimmu.2021.714175. eCollection 2021.

本文引用的文献

The right place for IL-1 inhibition in COVID-19.

Lancet Respir Med. 2021 Mar;9(3):223-224. doi: 10.1016/S2213-2600(21)00035-7. Epub 2021 Jan 22.

Hydroxychloroquine in COVID-19 Patients: Pros and Cons.

Front Pharmacol. 2020 Nov 19;11:597985. doi: 10.3389/fphar.2020.597985. eCollection 2020.

Combining Antivirals and Immunomodulators to Fight COVID-19.

Trends Immunol. 2021 Jan;42(1):31-44. doi: 10.1016/j.it.2020.11.003. Epub 2020 Nov 13.

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12.

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28.

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).

BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.

N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.

Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19.

Lancet. 2020 Oct 24;396(10259):e61-e62. doi: 10.1016/S0140-6736(20)32132-2. Epub 2020 Oct 9.

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.

N Engl J Med. 2020 Oct 22;383(17):1645-1656. doi: 10.1056/NEJMoa2015294. Epub 2020 Oct 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Why Haven't We Found an Effective Treatment for COVID-19?

Front Immunol. 2021 Mar 31;12:644850. doi: 10.3389/fimmu.2021.644850. eCollection 2021.

Commentary: Why Haven't We Found an Effective Treatment for COVID-19?

Front Immunol. 2021 Jul 5;12:714175. doi: 10.3389/fimmu.2021.714175. eCollection 2021.

The evolution of clinical trials in response to COVID-19.

Med J Aust. 2021 Apr;214(7):332-332.e1. doi: 10.5694/mja2.50991. Epub 2021 Mar 22.

The Biometeorology of COVID-19: A Novel Therapeutic Strategy?

Acta Medica (Hradec Kralove). 2020;63(4):202-204. doi: 10.14712/18059694.2020.65.

Letter from China: Managing the second-wave COVID-19 outbreak in Beijing.

Respirology. 2021 Mar;26(3):275-276. doi: 10.1111/resp.14002. Epub 2021 Jan 5.

Neutrophils in COVID-19.

Front Immunol. 2021 Mar 25;12:652470. doi: 10.3389/fimmu.2021.652470. eCollection 2021.

Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection.

J Biol Chem. 2021 Jan-Jun;296:100135. doi: 10.1074/jbc.REV120.015980. Epub 2020 Dec 6.

Developing Guidelines Before, During, and After the COVID-19 Pandemic.

Ann Intern Med. 2020 Dec 15;173(12):1012-1014. doi: 10.7326/M20-4907. Epub 2020 Sep 15.

COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?

Autoimmun Rev. 2020 Dec;19(12):102683. doi: 10.1016/j.autrev.2020.102683. Epub 2020 Oct 27.

Immunology Lessons from the SARS-CoV-2 Pandemic.

Annu Rev Immunol. 2021 Apr 26;39:v-vii. doi: 10.1146/annurev-iy-39-030121-100001. Epub 2021 May 3.

引用本文的文献

Anti-viral effect of usenamine a using SARS-CoV-2 pseudo-typed viruses.

Heliyon. 2023 Oct 28;9(11):e21742. doi: 10.1016/j.heliyon.2023.e21742. eCollection 2023 Nov.

Treating COVID-19: Targeting the Host Response, Not the Virus.

Life (Basel). 2023 Mar 6;13(3):712. doi: 10.3390/life13030712.

Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19.

Crit Care. 2023 Mar 16;27(1):112. doi: 10.1186/s13054-023-04388-8.

A patchy theoretical model for the transmission dynamics of SARS-Cov-2 with optimal control.

Sci Rep. 2022 Oct 25;12(1):17840. doi: 10.1038/s41598-022-21553-1.

Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease.

Scand J Immunol. 2021 Nov;94(5):e13101. doi: 10.1111/sji.13101. Epub 2021 Sep 16.

Commentary: Why Haven't We Found an Effective Treatment for COVID-19?

Front Immunol. 2021 Jul 5;12:714175. doi: 10.3389/fimmu.2021.714175. eCollection 2021.

本文引用的文献

The right place for IL-1 inhibition in COVID-19.

Lancet Respir Med. 2021 Mar;9(3):223-224. doi: 10.1016/S2213-2600(21)00035-7. Epub 2021 Jan 22.

Hydroxychloroquine in COVID-19 Patients: Pros and Cons.

Front Pharmacol. 2020 Nov 19;11:597985. doi: 10.3389/fphar.2020.597985. eCollection 2020.

Combining Antivirals and Immunomodulators to Fight COVID-19.

Trends Immunol. 2021 Jan;42(1):31-44. doi: 10.1016/j.it.2020.11.003. Epub 2020 Nov 13.

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12.

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28.

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).

BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.

N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.

Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19.

Lancet. 2020 Oct 24;396(10259):e61-e62. doi: 10.1016/S0140-6736(20)32132-2. Epub 2020 Oct 9.

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.

N Engl J Med. 2020 Oct 22;383(17):1645-1656. doi: 10.1056/NEJMoa2015294. Epub 2020 Oct 7.